pubmed-article:17379063 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C1332225 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C1134535 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C2347880 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C1831743 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C0338248 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
pubmed-article:17379063 | lifeskim:mentions | umls-concept:C0919274 | lld:lifeskim |
pubmed-article:17379063 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:17379063 | pubmed:dateCreated | 2007-3-23 | lld:pubmed |
pubmed-article:17379063 | pubmed:abstractText | To determine the safety and outcome following standard-dose ibritumomab tiuxetan followed by BEAM high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma. | lld:pubmed |
pubmed-article:17379063 | pubmed:language | eng | lld:pubmed |
pubmed-article:17379063 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17379063 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17379063 | pubmed:month | Apr | lld:pubmed |
pubmed-article:17379063 | pubmed:issn | 0301-472X | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:Ben-BassatIsa... | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:NaglerArnonA | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:ShimoniAvicha... | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:AvigdorAbraha... | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:HardanIzharI | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:YerushalmiRon... | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:OksmanYakovY | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:ZwasS TzilaST | lld:pubmed |
pubmed-article:17379063 | pubmed:author | pubmed-author:Shem-TovNogaN | lld:pubmed |
pubmed-article:17379063 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17379063 | pubmed:volume | 35 | lld:pubmed |
pubmed-article:17379063 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17379063 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17379063 | pubmed:pagination | 534-40 | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:meshHeading | pubmed-meshheading:17379063... | lld:pubmed |
pubmed-article:17379063 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17379063 | pubmed:articleTitle | Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. | lld:pubmed |
pubmed-article:17379063 | pubmed:affiliation | Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il | lld:pubmed |
pubmed-article:17379063 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17379063 | pubmed:publicationType | Clinical Trial | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17379063 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17379063 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17379063 | lld:pubmed |